Studies have found that[4] the most common irAEs of programmed cell death 1 inhibitors are skin manifestations, accounting for about 30% to 40% of immune-related adverse events, including rash, pruritus, vitiligo, etc. In addition to the above, the severe skin adverse events that may occur after the use of Sintilimab include bullous dermatitis, toxic epidermal necrolysis, exfoliative dermatitis and so on, which can endanger life and deserve attention. This evidence concerns the gene PDCD1 and vitiligo.